News – Page 1105 – Endpoints News

The Endpoints 100 CEO Survey: Execs offer a big thumbs up for Gottlieb and some suggestions for making the FDA a ...

8 years ago

Patrick Soon-Shiong accused of more conflicts of interest; Eli Lilly expands in San Diego

8 years ago

UK regulators green-light early access to Santhera’s Raxone for Duchenne MD

8 years ago

FDA padlocks any new human tests on Seattle Genetics’ cancer drug in the wake of more deaths

8 years ago

In another setback, Kamada pulls an application at the EMA and retrenches on a PhIII drug

8 years ago

Novartis’ big PhIII for canakinumab scores a surprise win helping heart attack patients

8 years ago

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

8 years ago

Top 20 blockbuster drugs in the late-stage pipeline — EvaluatePharma

8 years ago

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

8 years ago

The small, virtual team at Syntimmune bags a $50M round in the march toward a pivotal test

8 years ago

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech

8 years ago

Running out of cash and cited on fraud charges, ImmunoCellular retreats on PhIII and cries for help

8 years ago

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

8 years ago

Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform

8 years ago

Cheers! Endpoints News turns 1 today — and we're unwrapping info on a new subscription plan

8 years ago

In wake of a trial disaster, Seattle Genetics files sBLA; Egalet takes a dive on a CRL

8 years ago

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

8 years ago

Wobbly Parexel International snapped up for $5B in latest CRO buyout

8 years ago

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

8 years ago

Several CEOs and 17 years later, Melinta scores an FDA OK for its antibiotic

8 years ago

AstraZeneca and GlaxoSmithKline come to a peaceful settlement of their tug of war over Luke Miels

8 years ago

Massachusetts Governor Charlie Baker unveils a $500M program to keep its big biotech hub booming

8 years ago

Novartis chief says Trump visa restrictions sour US hiring plans; Parexel and Sanofi to develop wearable devices

8 years ago

Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep

8 years ago

First page Previous page 1102 1103 110411051106 1107 1108 Next page Last page